Why the study?
What is the clinical profile, efficacy, and safety of trandolapril for blood pressure control?
What is the clinical profile, efficacy, and safety of trandolapril for blood pressure control?
Trandolapril is an effective, long-acting ACE inhibitor that controls blood pressure in approximately 60% of patients with a safety profile similar to other drugs in its class.
Answers are grounded in this paper and cite their sources.
Supports trandolapril as a hypertension option; leaves open need for updated head-to-head RCTs.
Trandolapril is a new angiotensin converting enzyme (ACE) inhibitor that effectively lowers blood pressure in doses up to 2 mg. Only a small additional effect is seen with higher doses. The drug is transformed in vivo to the active metabolite trandolaprilat. When renal function is severely impaired a dose reduction may be necessary because the clearance of trandolaprilat is significantly correlated to creatinine clearance. Trandolapril has a sustained action that is reflected in long-lasting inhibition of ACE, even after discontinuation of treatment. Blood pressure is controlled by the drug in about 60% of patients with a side effect profile that is comparable to that of the other ACE inhibitors. Trandolapril can be given safely over a prolonged period of time.
No takes yet. Share an insight, caveat, or question.
P DELEEUW (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: